Status:
UNKNOWN
Psoriatic Immune Response to Tildrakizumab
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Sun Pharmaceutical Industries Limited
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Detailed Description
This is a one-arm, open-label study to examine the effect of Tildrakizumab on cutaneous and blood immune cells of psoriatic patients. Ten subjects with moderate to severe psoriasis will be enrolled. B...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Patients with moderate-severe psoriasis or \> 5% body surface area affected.
Exclusion
- taking systemic immunosuppressives in the last 4 weeks
- pregnancy
- severe immunodeficiency (either from genetic or infectious causes).
- tuberculosis or other active serious infection
- active systemic malignancy.
- breast-feeding
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05390515
Start Date
September 1 2022
End Date
September 1 2025
Last Update
August 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94115